Zydus Cadila receives USFDA nod to market fluconazole tablets
NEW DELHI: Drug firm Zydus Cadila has received approval from the US health regulator to market fluconazole tablets used for the treatment of fungal infections.
The company also received approval for Clobetasol Propionate spray used in the treatment of various skin disorders.
"Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market fluconazole tablets in strengths of 50 mg, 100 mg, 150 mg and 200 mg and Clobetasol Propionate spray, 0.05 per cent," Cadila Healthcare said in a BSE filing.
The group now has more than 105 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of the filing process in 2003-04 fiscal, it added.
Shares of Cadila Healthcare were trading 4.55 per cent higher at Rs 449 apiece on BSE.
The company also received approval for Clobetasol Propionate spray used in the treatment of various skin disorders.
"Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market fluconazole tablets in strengths of 50 mg, 100 mg, 150 mg and 200 mg and Clobetasol Propionate spray, 0.05 per cent," Cadila Healthcare said in a BSE filing.
The group now has more than 105 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since the commencement of the filing process in 2003-04 fiscal, it added.
Shares of Cadila Healthcare were trading 4.55 per cent higher at Rs 449 apiece on BSE.
